文献速递抗栓抗凝管理抗菌药物管理

外周动脉疾病介入术后抗血栓治疗管理

Antithrombotic therapy for postinterventional management of peripheral arterial disease.
PubMed 文献 · Am J Health Syst Pharm · 2020-01-01

本文综述了症状性外周动脉疾病(PAD)患者下肢血运重建术后抗血栓药物治疗的证据。抗血栓策略包括双联抗血小板治疗(DAPT)、抗凝、抗血小板联合抗凝及西洛他唑联合单抗血小板治疗。结论认为高质量证据相当缺乏,尚无特定治疗能持续改善患者结局,强化治疗获益仅限于预防靶动脉再闭塞,而出血风险增加可导致显著病残和死亡。

要点

  • PAD下肢血运重建术后常强化抗血栓治疗以预防靶动脉再狭窄并对抗介入所致促血栓状态。
  • 随机临床试验亚组分析提供低质量证据支持膝下人工血管旁路移植者用DAPT、静脉旁路移植者用抗凝。
  • 西洛他唑联合阿司匹林在数项小型随机试验中显示可预防低血栓风险患者腔内介入后靶血管再闭塞。

核心结论

  • 下肢血运重建患者最佳抗血栓方案的高质量证据相当缺乏,尚无特定治疗被证明能持续改善患者结局。
  • 启动强化抗血栓治疗应仔细评估其风险-获益特征。

研究设计与样本

  • 本文为综述,评估症状性PAD患者下肢血运重建术后抗血栓药物治疗的证据。

主要发现

  • 随机临床试验数据亚组分析提供低质量证据:膝下人工血管旁路移植患者使用DAPT,静脉旁路移植患者使用抗凝。
  • 数项小型随机试验显示,西洛他唑联合阿司匹林可预防低血栓风险患者腔内介入后靶血管再闭塞。

临床怎么用

  • 下肢血运重建术后考虑强化抗血栓治疗时,应权衡预防靶动脉再闭塞的获益与出血风险增加可能导致的病残和死亡。

局限性

  • 下肢血运重建患者最佳抗血栓方案的高质量证据相当缺乏。
  • 强化抗血栓治疗的获益仅限于预防靶动脉再闭塞,且出血风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evidence on the use of antithrombotic pharmacotherapy in patients undergoing revascularization of lower extremities for symptomatic peripheral arterial disease (PAD) is reviewed. SUMMARY: Individuals with PAD can experience leg pain, intermittent claudication, critical limb ischemia, and acute limb ischemia. In such patients, revascularization may be indicated to improve the quality of life and to prevent amputations. Antithrombotic therapy is often intensified in the postrevascularization period to prevent restenosis of the index artery and to counteract the prothrombotic state induced by the intervention. Therapeutic modalities include dual antiplatelet therapy (DAPT), anticoagulation, a combination of antiplatelet and anticoagulation therapy, and addition of cilostazol to single antiplatelet therapy. Subgroup analyses of data from randomized clinical trials provided low-quality evidence for the use of DAPT in patients with a below-knee prosthetic bypass graft and anticoagulation for those with a venous bypass graft. Cilostazol, when added to aspirin therapy, has been shown to prevent index vessel reocclusion after an endovascular intervention in patients at low risk for thrombosis in several small randomized trials. CONCLUSION: There is a considerable paucity of high-quality evidence on the optimal antithrombotic regimen for patients undergoing lower extremity revascularization, with no particular therapy shown to consistently improve patient outcomes. The decision to initiate intensified antithrombotic therapy should include a close examination of its risk-benefit profile. The demonstrated benefit of such treatment is restricted to the prevention of index artery reocclusion, while an increased risk of bleeding may lead to significant morbidity and mortality.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Zavgorodnyaya D, Knight TB, Daley MJ, et al. Antithrombotic therapy for postinterventional management of peripheral arterial disease. Am J Health Syst Pharm. 2020. PMID: 31930282. doi:10.1093/ajhp/zxz315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。